Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience

Brachytherapy

Volumn 11, Issue 4, 2012, Pages 245-249

  Zelefsky, Michael J ^a   Chou, Joanne F ^a   Pei, Xin ^a   Yamada, Yoshiya ^a   Kollmeier, Marisa ^a   Cox, Brett ^a   Zhang, Zhigang ^a   Schechter, Michael ^a   Cohen, Gil'ad N ^a   Zaider, Marco ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; D 90; Iodine 125; Nomogram; Prostate cancer; Prostate specific antigen

Indexed keywords

IODINE 125; IRIDIUM 192; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMICAL TUMOR CONTROL; BRACHYTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW YORK; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862572095     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.08.003     Document Type: Article

References (16)

1. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
2. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533.
3. Henry A.M., Al-Qaisieh B., Gould K., et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys 2010, 76:50-56.
4. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
5. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:65-70.
6. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998, 41:101-108.
7. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcomes for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
8. Harrell F.E., Califf R.M., Pryor D.B., et al. Evaluating the yield of medical tests. JAMA 1982, 247:2543-2546.
9. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
10. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176(4 Pt 1):1415-1419.
11. Zelefsky M.J., Yamada Y., Pei X., et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011, 77:986-990.
12. Fuchsjager M.H., Pucar D., Zelefsky M.J., et al. Predicting post-external beam radiation therapy relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys 2010, 78:743-750.
13. Vargas C., Martínez A., Galalae R., et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 2006, 9:245-253.
14. Kattan M.W., Potters L., Blasko J.C., et al. Pre-treatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001, 58:393-399.
15. Potters L., Roach M., Davis B.J., et al. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys 2010, 76:1061-1065.
16. Zelefsky M.J., Worman M., Cohen G.N., et al. Real-time intraoperative CT assessment of quality of permanent interstitial seed implantation for prostate cancer. Urology 2010, 76:1138-1142.